Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice Article Swipe
Related Concepts
Aromatase
Aromatase inhibitor
HER2 negative
Cancer
Medicine
Metastatic breast cancer
Oncology
Internal medicine
Breast cancer
Progression-free survival
Overall survival
Cancer research
Hope S. Rugo
,
Rachel M. Layman
,
Filipa Lynce
,
Xuan Liu
,
Benjamin Li
,
Lynn McRoy
,
Aaron B. Cohen
,
Melissa Estévez
,
Giuseppe Curigliano
,
Adam Brufsky
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2025.105570
· OA: W4413881464
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2025.105570
· OA: W4413881464
Our study, the largest real-world CDK4/6i comparative effectiveness study to date, demonstrated no significant rwPFS differences between 1L palbociclib, ribociclib, and abemaciclib, plus AI, in patients with HR-positive/HER2-negative mBC.
Related Topics
Finding more related topics…